Abiopharma

1 Press ReleaseInmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004San Diego, Shanghai and Hong Kong Tuesday, August 9, 2022 Inmagene Biopharmaceuticals (Inmagene) and HUTCHMED (China) Limited (HUTCHMED) (NasdaqAIMHCM HKEX13) announce today that the first participant, based in the United States, was dosed in a global Phase I trial of IMG-004, a non-covalent, reversible, third-generation Bruton Tyrosine Kinase (BTK) inhibitor. The Phase I study is a double-blind, randomized, placebo-controlled, single and multiple dose escalation study in healthy subjects. The study aims to explore IMG-004s safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects.